Trial
NCT04046107
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Regeneron Pharmaceuticals
Condition
Hepatitis B Virus
Intervention
Cemiplimab
Why stopped
Temporarily closed to enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-07